The proto-oncogene ROS1 encodes a receptor tyrosine kinase with an unknown
physiological role in humans. Somatic chromosomal fusions involving ROS1 produce …

Rearrangements of the ROS1 gene occur in 1–2% of non-small cell lung cancers (NSCLCs).
Crizotinib, a highly effective inhibitor of ROS1 kinase activity, is now FDA-approved for the …

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …

Context.—In 2013, an evidence-based guideline was published by the College of American
Pathologists, the International Association for the Study of Lung Cancer, and the Association …

This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC)
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …

The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) address all aspects of
management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the …

Purpose ROS1 rearrangement is a distinct molecular subset of non–small-cell lung cancer
(NSCLC). We investigated the efficacy and safety of ceritinib in patients with ROS1 …

Purpose Approximately 1% of lung adenocarcinomas are driven by oncogenic ROS1
rearrangement. Crizotinib is a potent inhibitor of both ROS1 and ALK kinase domains …

Despite tremendous progress in the last decade, lung adenocarcinoma still represents a
tumor with unfavorable prognosis when detected at advanced clinical stage. High-stage …

Background Non‐small cell lung cancer (NSCLC) is one of the most common human
malignancies and the leading cause of cancer‐related death. Over the past few decades …